Construction And Functional Verification Of Prevascularized Cgf/Gelma Composite Matrix

Vascularization is the key to tissue-engineered organoid construction. In this study, GelMA was used for the modification of concentrated growth factors (CGF), combined with acellular vascular matrix (ACVM)-0.25% human-like collagen I (HLC-I), developed in the previous research base, constructed a 3D cell-reconstructed CGF/GelMA-ACVM-0.25% HLC-I composite matrix, and its function in promoting vascular network generation in tissue engineering soft tissue repair was verified. CGF/GelMA-ACVM-0.25% HLC-I complex matrix was constructed, combining GMSCs and VELCs for 3D cell reconstruction of a natural soft tissue complex. The complexes' morphology, ultrastructure, physicochemical properties, and cytokine release were assessed using HE staining, SEM, FTIR, cyclic compression, lysis and ELISA. Biocompatibility and vascular formation were tested with CCK-8, live/dead assays, tube-forming test, cell scratch and Transwell invasion assays. In vivo experiments utilized bioreactor to construct natural-like soft tissues. Histological characteristics were assessed using HE, Masson, and immunofluorescence staining. Vascular network efficacy and mechanical properties were verified through small animal ultrasound imaging, tracer staining, and cyclic compression tests. CGF/GelMA-ACVM-0.25% HLC-I composite matrix is biocompatible and promotes angiogenesis, aiding in the vascularized regeneration of tissue-engineered soft tissues. CGF/GelMA-ACVM-0.25% HLC-I composite matrix, created by modifying CGF with GelMA and combining it with ACVM-0.25%HLC-I, serves as excellent prevascularized material for tissue-engineered biomimetic soft tissues.